Clinical trials: Portal Vein Embolization
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma
Unsatisfactory immediate outcomes of Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) in surgery of cholangiocarcinoma suggested that patients with biliary cancer should not be treated by ALPPS.
- Trial name
- NCT03320980
- Testing
- RALPPS, portal vein embolization + major liver resection
- Volunteers
- 30 people
- Sponsor
- Moscow Clinical Scientific Center
Embolization, Vascular Tumor
Evaluation of a Simple-Prep Controlled Embolic
The objective of this study is to evaluate the safety and effectiveness of the GPX® Embolic Device when used as indicated for embolization requiring distal vessel penetration in 114 subjects in up to 25 investigational sites in…
- Conditions
- Embolization, Vascular Tumor, Renal Angiomyolipoma, Renal Cell Carcinoma
- Trial name
- GPX (NCT06453642)
- Testing
- GPX® Embolic Device
- Where
- 20 sites in United States, Canada and 1 more
- Volunteers
- 114 people
- Sponsor
- Fluidx Medical Technology, Inc.
Liver Cancer, Surgery
HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies
This observational clinical cohort study aims to evaluate the clinical utility of LiverMultiScan in quantifying liver health prior to liver resection or TACE.
- Conditions
- Liver Cancer, Surgery, Liver Regeneration, Colorectal Cancer Metastatic
- Trial name
- Hepatica (NCT03213314)
- Testing
- Multiparameter magnetic resonance imaging
- Where
- 2 sites in United Kingdom
- Volunteers
- 149 people
- Sponsor
- University of Edinburgh
Liver Regeneration, Liver Cancer
ARAPS Study on Accelerated Liver Regeneration
Liver resection is the golden standard in the treatment of hepatic malignancies. The size and function of the remnant liver is a major concern.
- Conditions
- Liver Regeneration, Liver Cancer, Liver Metastases, Liver Failure
- Trial name
- ARAPS (NCT04107324)
- Testing
- ARAPS, PVE
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- University of Aarhus
Hepatocellular Carcinoma
PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer
This is a multicenter, randomized, positive parallel controlled clinical study to evaluate the short-term and long-term efficacy and safety of PVL/PVE combined with DEB-TACE in the treatment of unresectable patients with large or…
- Trial name
- CCGLC-004 (NCT05103007)
- Testing
- DEB-TACE, PVL/PVE+DEB-TACE
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Tongji Hospital
Portal Vein Occlusion, Cholangiocarcinoma, Perihilar
Portal Vein Embolization Using Coils Plus TAGM vs Multiple Coils for Patients With Perihilar Cholangiocarcinoma or Hepatocellular Carcinoma
The aim of this study is to investigate the differences of safety and liver hypertrophy between portal vein embolization (PVE) using coils plus tris-acryl gelatin microspheres (TAGM) and multiple coils in patients with perihilar…
- Conditions
- Portal Vein Occlusion, Cholangiocarcinoma, Perihilar, Hepatocellular Carcinoma, Liver; Hypertrophy, Acute
- Trial name
- NCT04386772
- Testing
- PVE with coils plus TAGM, PVE with multiple coils
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Varicocele, Endoleak
EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications
The EASYX™ Liquid Embolic is a new injectable, precipitating polymeric agent for the obliteration of vascular spaces through direct puncture or catheter access performed under X-ray guidance.
- Conditions
- Varicocele, Endoleak, Portal Vein Thrombosis, Bleeding
- Trial name
- EASYX-1 (NCT03477149)
- Testing
- Easyx
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Colorectal Cancer, Metastatic Cancer
Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer
RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure…
- Trial name
- NCT00028626
- Testing
- embolization therapy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Liver Metastases, Liver Cancer
TANGO-LIVER Three Arm Nuclear Growth Observation in Liver Surgery
Liver resection is the treatment of choice in patients with malignant liver lesions. Unfortunately, the surgery is not always an option, as in same patients the future remnant liver (FRL) is too small to supply all the functions.
- Conditions
- Liver Metastases, Liver Cancer, Liver Neoplasms, Liver Metastasis Colon Cancer
- Trial name
- TANGO-LIVER (NCT06050200)
- Testing
- PVE, LVD, ALPPS
- Where
- Poland
- Volunteers
- 154 people
- Sponsor
- Medical University of Warsaw
Colorectal Cancer, Liver Metastases
Alternative to Two-Stage Hepatectomy
Two-stage hepatectomy with or without portal vein embolization allows to treat multiple bilobar metastases expanding surgical indications for these patients.
- Trial name
- NCT00587756
- Testing
- One-stage ultrasound guided hepatectomy
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- University of Milan
Liver and Intrahepatic Bile Duct Carcinoma
CT Perfusion Scans in Detecting Changes in Blood Flow to the Liver After Portal Vein Embolization
This trial studies the use of computed tomography (CT) perfusion scans in detecting changes in blood flow to the liver after portal vein embolization in patients with liver cancer.
- Trial name
- NCT03990623
- Testing
- Computed Tomography Perfusion Imaging, Liver Biopsy
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Liver Cancer, Hepatocellular Carcinoma (HCC)
The Dragon PLC Trial (DRAGON-PLC)
The goal of the DRAGON PLC clinical trial is to determine whether portal vein embolization (PVE) combined with hepatic vein embolization (HVE) improves resectability and overall survival in patients with initially unresectable…
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma (HCC), Cholangiocarcinoma
- Trial name
- NCT06914648
- Testing
- Portal Vein Embolization, Hepatic Vein Embolization
- Where
- 55 sites in United States, Australia and 10 more
- Volunteers
- 358 people
- Sponsor
- Maastricht University
Colorectal Cancer Liver Metastases
DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE
Brief Summary: Some colorectal liver metastases can only be resected after inducing liver regeneration by portal vein embolization (PVE) to increase size function of the future liver remnant (FLR).
- Trial name
- DRAGON (NCT04272931)
- Testing
- Portal and Hepatic Vein Embolization
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 111 people
- Sponsor
- Maastricht University
Liver Cancer, Liver Metastases
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE.
- Trial name
- NCT07717437
- Where
- 31 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Maastricht University Medical Center
Liver Metastasis Colon Cancer
Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant
The hypothesis is that liver venous deprivation (LVD) could strongly improve hypertrophy of the future remnant liver (FRL) at 3 weeks, as compared to portal vein embolization (PVE) in patient with liver metastases from…
- Trial name
- HYPER-LIV01 (NCT03841305)
- Testing
- Liver preparation before major hepatectomy
- Where
- 12 sites in France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Montpellier
Liver Tumors
Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)
One of the limiting factors in the execution of a liver resection, in particular an extended liver resection, it's represented by the future remnant liver (FRL) after hepatic surgery.
- Trial name
- LAPS (NCT02184182)
- Testing
- VLS ablation/portal ligation/hepatectomy
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Ospedaliera di Padova
Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of…
- Trial name
- YES-P (NCT01887717)
- Testing
- TheraSphere®, Sorafenib
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Vascular Anomalies, Hemorrhage
Safety and Efficacy Of Amber Peripheral Liquid Embolic System
A prospective, single-arm, multicenter, open-label, First-in-Human \& Pivotal Study to assess the safety and efficacy of amber SEL-P in 70 patients requiring peripheral embolization: vascular anomalies, hemorrhages, aneurysms…
- Conditions
- Vascular Anomalies, Hemorrhage, Aneurysm, Pseudoaneurysm
- Trial name
- OPAL (NCT06456125)
- Testing
- amber SEL-P Peripheral Liquid Embolic System
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- LVD Biotech S.L
Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR)
The DRAGON 2 Trial
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
- Trial name
- DRAGON 2 (NCT05428735)
- Testing
- Embolization
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 348 people
- Sponsor
- Maastricht University